Angiogenesis and Non Small Cell Lung Cancer

Abstract

Non small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers. Despite improvements in treatment protocols the survival rate in NSCLC remains poor. An improved understanding of cancer biology has led to the investigation of angiogenesis in NSCLC development and progression by intratumoral microvessel count or expression of angiogenic markers. The prognostic significance of several frequently assessed angiogenic factors and current antiangiogenic strategies which proved to be particularly promising in combination with chemo therapeutic agents for clinical management of NSCLC are here reviewed.

Anti-Angiogenic Effectiveness of the Pomegranate Against Benzo(a)Pyrene Induced Lung Carcinoma in Mice

“…It has been experimentally revealed that sold tumors cannot grow beyond 1-2 mm in diameter without angiogenesis (Folkman, 1990). Tumor growth is dependent on the balance between increasing tumor-cell numbers through the proliferation of cells and decreasing numbers through an apoptotic process (Metodieva, 2008). If tumor angiogenesis is not sufficient, apoptotic cell death is accelerated the tumor growth is inhibited (Holmgren et al, 1995).…”